Proposals to allow orthoptists to sell, suply and administer medicines under exemtions within the Human Medicines Regulations (2012) across the United Kingdom – NHS England

The NHS is now consulting on proposals to enable orthoptists who have undergone the appropriate training, to be able to sell, supply and administer medicines under exemptions within the Human Medicines Regulations (2012) across the United Kingdom. The proposed changes will

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) – NICE technology appraisal guidance [TA329]

Infliximab (also known as Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) are recommended. They are possible treatments for adults with moderate to severe ulcerative colitis if conventional therapy hasn’t worked or isn’t suitable. Infliximab is also recommended as